Sepsivac
{{Infobox drug
| drug_name =
| INN =
| type =
| image =
| alt =
| caption =
| pronounce =
| tradename =
| Drugs.com =
| MedlinePlus =
| pregnancy_AU =
| pregnancy_AU_comment =
| pregnancy_category=
| routes_of_administration =
| ATCvet =
| ATC_prefix =
| ATC_suffix =
| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_CA_comment =
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK =
| legal_UK_comment =
| legal_US =
| legal_US_comment =
| legal_EU =
| legal_EU_comment =
| legal_UN =
| legal_UN_comment =
| legal_status =
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action=
| excretion =
| synonyms = Mycobacterium w (heat killed)
| CAS_number = 2781058-36-2
| PubChem =
| DrugBank =
| IUPAC_name =
| chemical_formula =
| molecular_weight =
}}
Sepsivac is a drug developed by Cadila Pharmaceuticals to treat gram-negative sepsis. The active ingredient is heat-killed Mycobacterium w, a non-pathogenic strain of Mycobacterium. As an immunomodulatory, it modulates the immune system of the body and hence significantly reduces mortality rate in patients with gram negative sepsis. Sepsivac is a drug developed by CSIR and Cadila Pharmaceuticals under New Millennium Indian Technology Leadership Initiative (NMITLI) programme.{{Cite web|url=https://science.thewire.in/health/covid-19-csir-gram-negative-sepsis-sepsivac-clinical-trials/|title=Indian Researchers Plan Clinical Trials of Sepsis Drug Against New Coronavirus| vauthors = Singh J |date= 22 April 2020 |website=The Wire Science|language=en-GB|access-date=28 April 2020}} In many cases, Sepsivac has proven to provide effective care and relief to COVID patients.{{Cite web| vauthors = Chakrabarti, Ganguly |title=Is there a way to tame the Covid virus?|url=https://www.thehindubusinessline.com/opinion/is-there-a-way-to-tame-the-covid-virus/article34442455.ece | date = 29 April 2021 |access-date= 30 April 2021 |website=@businessline|language=en}}
Sepsivac is approved by the Drug Controller General of India (DCGI) for treatment of sepsis or septic shock.{{cite web | url = https://www.cadilapharma.com/sepsivac-sepsis-saviour-cadila/ | title = Sepsivac – A First-In-The-World Innovation for Sepsis Management | publisher = Cadila Pharma }}{{bsn|date=July 2022}}
__TOC__
Mechanism
In patients with sepsis, in response to an infection, many pro-inflammatory and anti-inflammatory cytokines are generated in the body. However, some of the cytokines also cause inflammation in the organs of the body, which might be harmful. Immunomodulator drugs such as Sepsivac regulate this host immune response.{{Cite news| vauthors = Koshy J |url=https://www.thehindu.com/sci-tech/health/coronavirus-drug-for-sepsis-to-be-tested-for-covid-19/article31399594.ece|title=Coronavirus {{!}} Drug for sepsis to be tested for COVID-19|date=2020-04-21|work=The Hindu|access-date=28 April 2020|language=en-IN|issn=0971-751X}} Sepsivac is found to be safe in patients with no systematic side-effects. It can be used in combination with other treatments to manage a patient in critical care setting.{{Cite web|url=https://www.indiaspend.com/gram-negative-sepsis-drug-to-be-trialled-for-treating-critically-ill-covid-19-patients/|title=Gram-negative sepsis drug to be trialled for treating critically-ill COVID-19 patients | vauthors = Paliath S |date= 22 April 2020 |website=www.indiaspend.com|language=en-US|access-date=28 April 2020}}
Sepsivac and COVID
Scientists at CSIR found similarities between the clinical characteristics of patients with gram-negative sepsis and COVID-19. In association with Cadila Pharmaceuticals, the researchers are now working on initiating a randomised, blinded, controlled clinical trial to evaluate Sepsivac's efficacy to reduce mortality in critically ill COVID-19 patients. The repurposed drug will boost the immunity of the body and limit the spread of COVID-19 and increase the recovery rate.{{Cite web |url= https://www.newindianexpress.com/nation/2020/apr/24/sepsivac-to-be-tested-for-covid-19-treatment-2134537.html |title=Sepsivac to be tested for COVID-19 treatment|website=The New Indian Express | date = 24 April 2020 |access-date= 28 April 2020 }} The clinical trials will be conducted at national hospitals including PGIMER Chandigarh, AIIMS New Delhi, and AIIMS, Bhopal.{{Cite web | vauthors = Ray K |url=https://www.deccanherald.com/science-and-environment/50-yr-old-bacteria-drug-makes-a-comeback-in-fight-against-coronavirus-829105.html|title=50-yr-old bacteria drug makes a comeback in fight against coronavirus|date= 23 April 2020 |website=Deccan Herald |language=en |access-date=28 April 2020}}